IQV: Revenue grew 8% in Q3 as both segments expanded; R&D backlog was reset for inactive trials

What happened

IQVIA reported third-quarter revenue of $4.428 billion, up 8.0% from a year earlier, with diluted earnings per share of $2.10. Both business segments grew revenue and profit. Remaining performance obligations were $34.2 billion, and a $2.1 billion reassessment of inactive-trial backlog affected Research & Development Solutions.

Confirmed

Global impact / market context

Remaining performance obligations, which means contracted work not yet billed, signal future revenue visibility. The $2.1 billion inactive-trial backlog reassessment may reduce how much of that contracted work converts to revenue, so investors weigh steady 8% growth against the possibility of slower Research & Development Solutions bookings.

Analyst inference

For a healthcare data and clinical-research company, backlog quality affects revenue predictability. Resetting inactive trials removes work unlikely to restart from the pipeline, which can improve reporting clarity but may signal weaker demand in that segment and shift investor attention to new contract wins.

Analyst inference

What to watch

1. Watch whether future disclosures quantify how much of the $34.2 billion remaining performance obligations management still expects to convert into revenue, versus the portion tied to inactive trials. Confirmed
2. Management could disclose new booking trends and whether the $2.1 billion inactive-trial backlog reset is a one-time cleanup or reflects a recurring pattern of stalled trials. Proposed
3. If Research & Development Solutions bookings stay weak, future revenue growth may slow, so watch segment-level revenue and profit next quarter to see if the 8% pace holds. Analyst inference

Evidence

• Original source link unavailable